Pharsight

Jadenu patents expiration

JADENU's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6596750 NOVARTIS PHARMS CORP Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Jun, 2017

(6 years ago)

US6465504 NOVARTIS PHARMS CORP Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)

US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(10 years from now)

Jadenu is owned by Novartis Pharms Corp.

Jadenu contains Deferasirox.

Jadenu has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Jadenu are:

  • US6596750
  • US6465504

Jadenu was authorised for market use on 30 March, 2015.

Jadenu is available in tablet;oral dosage forms.

Jadenu can be used as method of treating chronic iron overload.

The generics of Jadenu are possible to be released after 21 November, 2034.

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
Orphan Drug Exclusivity(ODE) Jan 23, 2020
M(M-239) Dec 12, 2021
Orphan Drug Exclusivity(ODE-39) Jan 23, 2020
M(M-263) Jul 23, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: Method of treating chronic iron overload

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents